IGF1 and Parkinson disease: Considering the previously described higher levels of IGF-1 in early phases of neurodegenerative disorders, studying early stages of PD without the conferring effects of treatment appear the best point in the disease course to evaluate the possible role of IGF-1 in the central pathophysiology of PD.